We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Nvx2.5

Navitoclax Research

Mostly mechanism / observationalLimited safety

5 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Navitoclax studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from mixed-quality meta-analyses and randomised trials published 2014–2020.

Based on 5 studies · 1 meta-analysis

Confidence

Moderate

By outcome

Senescence & aging
Mostly mechanism / observational5 studies
Safety profile
Too few graded studies1 study

Older research base

Newest study from 2020 · Latest meta-analysis: 2014

20142020

1ReviewCited 849×2020

Senolytic drugs are reviewed from discovery toward clinical translation.

Kirkland, Tchkonia · Journal of internal medicine (2020)

Review of senolytics including D+Q, fisetin, and navitoclax
Summarizes preclinical evidence and the early human trials
Frames the translational gap and safety considerations

View source Free full text

2Animal2016

Clearance of senescent cells by ABT263 rejuvenated aged and irradiated hematopoietic stem cells in mice.

Chang, Wang, Shao, Laberge, Demaria, Campisi · Nature medicine (2016)

Navitoclax (ABT263) cleared senescent cells in aged and total-body-irradiated mice
Rejuvenated hematopoietic and muscle stem-cell function
Influential proof that pharmacologic senolysis can restore stem-cell fitness

View source

3Preclinical2016

Navitoclax was identified as a senolytic agent targeting the Bcl-2 family of anti-apoptotic proteins.

Zhu, Tchkonia, Fuhrmann-Stroissnigg, Dai, Ling, Stout · Aging cell (2016)

Identified navitoclax as a senolytic via Bcl-2-family inhibition
Established the mechanism senescent cells depend on for survival
A founding senolytic-screen result alongside dasatinib/quercetin work

View source

4Animal2018

Clearance of senescent glial cells prevented tau-dependent pathology and cognitive decline in mice.

Bussian, Aziz, Meyer, Swenson, van Deursen, Baker · Nature (2018)

Senescent glial cells drive tau pathology; clearing them (navitoclax-class senolysis) was protective
Reduced neurodegeneration and preserved cognition in a tau mouse model
Extends the senolytic rationale to neurodegeneration

View source

5Meta-Analysis2014

Thrombocytopenia is the primary dose-limiting toxicity of navitoclax, with a distinct time profile from chemotherapy.

Kaefer, Yang, Noertersheuser, Mensing, Humerickhouse, Awni · Cancer chemotherapy and pharmacology (2014)

PK/PD modeling analysis of navitoclax across human (oncology) studies
Characterized thrombocytopenia as the on-target dose-limiting toxicity
Quantifies the central safety problem for chronic senolytic use

View source

View in Research Library

Navitoclax Research

Mostly mechanism / observational

Senolytic drugs: from discovery to translation.

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice.

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.

Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline.

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia.